JPMorgan Downgrades Intra-Cellular Therapies (ITCI) to Neutral

January 31, 2020 4:41 AM EST
Get Alerts ITCI Hot Sheet
Price: $34.36 -0.41%

Rating Summary:
    15 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 15 | New: 24
Trade Now! 
Join SI Premium – FREE

JPMorgan analyst Jessica Fye downgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Overweight to Neutral with a price target of $26.00 (from $19.00).


For an analyst ratings summary and ratings history on Intra-Cellular Therapies click here. For more ratings news on Intra-Cellular Therapies click here.


Shares of Intra-Cellular Therapies closed at $22.97 yesterday.


You May Also Be Interested In





Related Categories

Analyst PT Change, Downgrades